Sir -Marshall et al. (1989) reported recently that a human fibroblast cell line from a member of a cancer-prone family (3437T) was six times more resistant than an equivalent cell line from a normal donor (GM38) to the bioreductive antitumour antibiotic mitomycin C. Interestingly, this resistance was seen only when the drug exposure was carried out under well oxygenated conditions, but not under hypoxic conditions (< 10 p.p.m. 02)-Similarly, a Chinese hamster ovary cell line with induced resistance to mitomycin C under oxic conditions did not exhibit comparable resistance under hypoxic conditions .
Compared to the normal human fibroblast line GM38, Marshall et al. (1989) reported that the resistant 3437T cell line exhibited substantially reduced levels of the enzyme DTdiaphorase or NAD(P)H: (quinone-acceptor) oxidoreductase (E.C.1.6.99.2) (Ernster et al., 1987) . Also, the DT-diaphorase inhibitor dicoumarol (3,3'-methylene-bis [4-hydroxycoumarin] ) was shown to decrease the aerobic sensitivity of the normal GM38 line but not the resistant 3437T line. The conclusion was drawn that DT-diaphorase may play an important role in the bioreductive activation of mitomycin C under oxic conditions, and that deficient expression of this enzyme by the 3437T cell line leads (at least in part) to aerobic resistance to the drug. Similarly, this resistance is mimicked to some extent in the normal GM38 line by dicoumarol inhibition of the enzyme.
A number of studies on the mechanism of action of mitomycin C have relied heavily on the use of dicoumarol as a specific inhibitor of DT-diaphorase to probe for the functional role of this enzyme (e.g. Keyes et al., 1984 Keyes et al., , 1985a Dulhanty et al., 1989) . In one series of studies, the intriguing result was obtained that dicoumarol was able to increase the sensitivity of EMT6 mouse mammary tumour cells to mitomycin C under hypoxic conditions, yet decreased the sensitivity of the same cells when exposed to the drug under oxic conditions (Keyes et al., 1984 (Keyes et al., , 1985a . The increased toxicity under hypoxic conditions was related to the stimulation by dicoumarol of the amount of alkylating species generated (Keyes et al., 1984) . The clear and reasonable implication at the time the studies were conducted was that DT-diaphorase activates mitomycin C in air but serves to detoxify the same drug under hypoxia.
The proposed role for DT-diaphorase in the toxification of mitomycin C under aerobic conditions is contradictory to that which is generally thought to apply for simple quinones such as menadione (Lind et al., 1982; Thor et al., 1982; Morrison et al., 1984; Ernster et al., 1987) . The aerobic toxicity of such compounds arises via one-electron reduction to the semiquinone free radical by enzymes such as NADPH:cytochrome P-450 reductase, leading to production of toxic oxygen species by auto-oxidation in a futile cycle (Figure 1 ). These radicals cause DNA and membrane damage. Since DT-diaphorase is an obligatory two-electron donor (lyanagi & Yamazaki, 1970) , reduction of quinones by this enzyme bypasses the toxic semiquinone radical by direct formation of the relatively stable hydroquinone, which can then undergo conjugation (Figure 1) . Thus under aerobic conditions DT-diaphorase plays an important role in the cellular defense against oxygen stress caused by simple quinones, and inhibition by dicoumarol gives rise to increased toxicity (see Ernster et al., 1987) .
The picture is of course more complex with mitomycin C since toxicity under oxic conditions will arise not only via oxidative stress (Bachur et al., 1979; Pritsos & Sartorelli, 1986) but also through bioreductive activation to DNAalkylating species (Pan et al., 1984; Tomasz et al., 1987) . Under hypoxic conditions DNA adducts, including crosslinks, will predominate. It has been argued that both oneelectron and two-electron reduction will result in bioreductive alkylation (Tomasz et al., 1987; Hoey et al., 1988) . Nevertheless, the precise role of these two reduction mechanisms in this toxic pathway remains unclear.
Further complications to the ongoing controversy are suggested by correlations between DT-diaphorase activity and cytotoxicity obtained in two other recent studies. Pritsos et al. (1987) compared DT-diaphorase in three xenograft tumours grown in nude mice (human, equine and canine neoplasms) and found the lowest enzyme activity in the tumour with the greatest mitomycin C sensitivity. In addition, in vivo treatment of the sensitive tumour with mitomycin C resulted in a higher level of enzyme activity in the subsequently regrowing tumours. These correlations are consistent with a detoxifying function for DT-diaphorase in vivo. On the other hand, in the previously mentioned study of a Chinese hamster ovary cell line with induced resistance through exposure to mitomycin C under aerobic conditions in vitro, there was no measureable DT-diaphorase activity but a decrease in NADPH: cytochrome P-450 reductase Walton et al., 1989) . These results indicate a more predominant role for cytochrome P-450 reductase in governing mitomycin C sensitivity. This enzyme is known to metabolise mitomycin C (Bachus et al., 1979) .
Much of the evidence in the continuing debate of the role of DT-diaphorase in mitomycin C bioactivation comes from studies such as those discussed earlier utilising dicoumarol as an inhibitor of the enzyme. There has, however, always been some concern regarding the over-reliance on dicoumarol as a 0 0°2 -Conjugates 01 2 X putative inhibitor of mitomycin C metabolism by DT-diaphorase where the measured end-point is cytotoxicity and not modulation of bioreductive metabolism. The potential for dicoumarol to modify cytotoxicity via additional mechanisms is clear (Keyes et al., 1987; Akman et al., 1985) . In particular, dicoumarol was shown to increase hypoxic mitomycin C toxicity (but not reduce oxic toxicity) in L1210 cells with measurable DT-diaphorase activity (Keyes et al., 1987) . Potentiation of menadione toxicity in L1210 cells by a method not involving DT-diaphorase has also been proposed (Akman et al., 1985) . Indeed the authors of the various papers cited above, including Marshall et al. (1989) , have been appropriately cautious in pointing out the potential artefacts of this approach.
In view of the contentious role of DT-diaphorase in mitomycin C toxicity, it is surprising that until recently there has been no published attempt to demonstrate metabolism of the drug by the purified enzyme. Such studies have now been carried out with several enzyme preparations and the results directly contradict a role for the enzyme in modulating mitomycin C sensitivity and resistance. The drug acts not as a substrate but in fact as an inhibitor of DT-diaphorase purified from human kidney by affinity and hydroxyapatite chromatography. This was demonstrated initially by two of us (Schlager & Powis, 1988) and confirmed independently by the others (Walton & Workman, unpublished) . Mitomycin C is also not a substrate for DT-diaphorase purifed from rat liver (Powis & Schlager, unpublished) . In addition, no dicoumarol-inhibitable metabolism of mitomycin C could be identified in DT-diaphorase-rich preparations obtained from the Chester Beatty strain of the rat Walker tumour (see later) or the HT29 human colon carcinoma (Walton & Workman, unpublished) . In all cases the most direct assay involved analysis of mitomycin C using a sensitive and specific highperformance liquid chromotography assay, and we can now define the lower limit of measurable activity as <30 pmol min-' Unit' enzyme at 50 gM mitomycin C (where 1 Unit = 1 limol cytochrome c reduced per min). As a positive control, we confirmed the observation of the reduction of 2,5-diaziridinyl-3,6-bis-(carboethoxyamino)-1,4-benzoquinone (AZQ) by HT29 cells (Siegel et al., 1989) and also by Walker cells. Analogous to these findings was the demonstration that another complex quinone antitumour antibiotic, doxorubicin, was likewise not a substrate for rat liver DTdiaphorase (Wallin, 1986) . On the other hand, Pritsos et al. (1987) claimed that mitomycin C was a substrate for partially purified beef liver DT-diaphorase with a Km of 1.5ZlM, although the assay method and detailed data were not presented.
DT-diaphorase exists in multiple forms (Ernster et al., 1987) and it is conceivable that some forms but not others are able to bioactivate or detoxify mitomycin C. It is also possible that mitomycin C is metabolised by DT-diaphorase at a rate below the lower limit of analytical detection, but sufficient for biological activity. However, in view of the apparent inability of the human kidney, HT29 colon carcinoma and rat Walker tumour enzymes to metabolise mitomycin C as well as the potential for dicoumarol to exhibit pleiotropic pharmacological effects, we believe that evidence of dicoumarol modulation of cytotoxicity alone should no longer be accepted as evidence for the participation of DT-diaphorase in the bioactivation of this drug. Direct metabolic and enzymological data should be sought to complement such cytoxicity studies, so that the true role, if any, of DT-diaphorase in the metabolism of mitomycin C and related quinones can be definitively identified.
Should DT-diaphorase from a variety of sources fail to metabolise mitomycin C, it will be important to establish whether altered expression or activity of this enzyme is involved in other ways in the control of mitomycin C toxicity, or whether this is an epiphenomenon. It is interesting to note that rodent liver DT-diaphorase expression can be upregulated by two classes of xenobiotic inducers: (1) those such as polycyclic aromatics acting via the Ah locus and causing a simultaneous increase in phase 1 enzymes including cytochrome P1-450; and (2) an alternative group including tert-butylhydroquinone and redox-labile diphenols capable of inducing phase 2 enzymes, such as UDPG-glucuronyl transferases, which normally play a detoxication role (see De Long et al., 1987) . DT-diaphorase has been shown to exhibit co-ordinately increased level of mRNA expression with glutathione-S-transferase Ya and Yb genes in rat hepatic preneoplastic nodules induced during chemical carcinogenesis in the Solt-Farber model, apparently as a result of hypomethylation of the gene (see Pickett, 1987) . Exciting new possibilities have been revealed by the recognition of close similarities in the biochemical profiles of rat preneoplastic and neoplastic hepatocytes and of in vitro derived multidrug resistant cells (Moscow & Cowan, 1988; Burt & Thorgeirsson, 1988) . In both situations resistance to a range of toxins is seen; toxin accumulation is reduced; expression of the P-170 drug efflux membrane glycoprotein increases; protective phase 2 and related enzyme activities rise; and phase 1 enzymes may fall or rise. Thus expression of these various genes may depend on overlapping regulatory elements.
The role of DT-diaphorase in multidrug resistance is unknown. No up-regulation was observed in a multidrugresistant MCF-7 human breast cancer line showing increased expression of glutathione-S-transferase x and decreased aryl hydrocarbon hydroxylase activity; in fact a decrease in DTdiaphorase was seen (Vickers et al., 1989) . However, protein changes, including cytochrome P-450s, glutathione-Stransferases and even P-glycoprotein, are by no means consistent across all multidrug-resistant cell lines (neither is the cross-resistance profile), and a range of lines should now be examined to clarify this situation.
Increased expression of DT-diaphorase in tumour cells, including human breast and colon tumours, may be quite widespread (Koudstaal et al., 1975; Schor & Cornelisse, 1983; Schor, 1987; . In view of these general findings, the presence of high DT-diaphorase levels in the HT29 human colon carcinoma and Walker 256 tumour cell lines makes these tumours especially appropriate models. It is interesting to note that the Chester Beatty strain of the Walker 256 rat tumour, though now an undifferentiated carcinosarcoma, originally arose as a mammary carcinoma of typical adenomatous structure (Earle, 1935; Rosenoer et al., 1966) .
Despite the apparent inability to metabolise mitomycin C, DT-diaphorase may represent an important target for drug bioactivation. In support of this, the elegant recent work of Knox et al. (1988a, b) has shown that high expression of DT-diaphorase in the Chester Beatty Walker 256 rat accounts for the extreme sensitivity of this tumour to CB
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(5-[aziridin-1-yl]-2,4-dinitrobenz-1 -amide). DT- diaphorase reduces this agent in air to a highly toxic 4-hydroxylamine derivative. Moreover, we have recently shown similar activity for purified human kidney DT-diaphorase, and the Walker enzyme to have the ability to reduce the novel benzotriazine di-N-oxide hypoxic cell cytotoxin SR 4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide) (unpublished data).
In summary, DT-diaphorase appears to play a questionable role in mitomycin C resistance, and further work is required to resolve this issue. DT-diaphorase may, however, provide an attractive target for the design of novel bioreductive drugs for the treatment of human tumours shown specifically to express high levels or an unusual form of this intriguing enzyme.
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